The United States has one of the highest obesity rates in the developed world. About 40% of American adults live with obesity — more than 100 million people. Another 31.7% are overweight but not yet obese. Combined, nearly three in four US adults carry excess weight that raises their risk for diabetes, heart disease, certain cancers, and early death.
2026 brought the first genuinely encouraging data in two decades: the adult obesity rate has declined from its 2022 peak of 39.9% to an estimated 36.4%, according to Gallup’s June 2026 survey. That’s the lowest rate since 2018. Researchers attribute the decline directly to the widespread adoption of GLP-1 weight loss medications. For children, the picture is different — and more troubling. Childhood obesity has reached record highs and is not yet showing the same decline.
This article compiles the most current US obesity statistics, demographic breakdowns, economic costs, health consequences, and what the 2026 data tells us about where things are heading.
Key takeaways
- 36.4% of US adults currently have obesity (Gallup, June 2026) — down from a peak of 39.9% in 2022.
- 40.3% of US adults had obesity in the most recent CDC NHANES clinical data (2021–2023).
- 21.1% of US children ages 2–19 have obesity — a record high (CDC NHANES, 2021–2023).
- Obesity rates are highest among non-Hispanic Black adults (49.9%) and lowest among Asian adults (16.1%).
- Obesity costs the US healthcare system an estimated $445 billion annually in direct and indirect costs.
- A 2025 PubMed model projects $20.4 trillion in direct healthcare costs from obesity between 2023 and 2060.
- Obesity is directly linked to type 2 diabetes, heart disease, sleep apnea, osteoarthritis, and 13 types of cancer.
- For the first time in the modern obesity epidemic, a pharmacological intervention — GLP-1 drugs — is producing a measurable population-level decline in adult obesity rates.
Current adult obesity rates in the US
Two data sources give slightly different numbers in 2026, and both are worth understanding.
- CDC NHANES (clinical measurement): The most recent published clinical data — from the National Health and Nutrition Examination Survey, August 2021 to August 2023 — shows 40.3% of US adults have obesity and 9.4% have severe obesity (BMI ≥40). NHANES measures height and weight directly, making it the most accurate available measure.
- Gallup Health Survey (self-reported): Gallup’s June 2026 survey of 5,065 US adults estimates the current obesity rate at 36.4% — the lowest level since 2018. Gallup uses self-reported height and weight, which tends to underestimate obesity (people often report themselves as slightly taller and lighter than they are). But the trend line is reliable: the rate peaked at 39.9% in 2022 and has fallen consistently since.
The honest interpretation is that the true current adult obesity rate sits somewhere between 36.4% and 40%, with the most likely range around 37–39%. The direction — declining — is the most meaningful signal.
Obesity prevalence in the US was around 15% in 1980. It rose to 23.3% by the early 1990s and climbed steadily for four decades. Every single US state now has an adult obesity rate above 25%. Nineteen states had rates at or above 35% in 2024 — down from 23 states in 2023, the first time this number has declined.
The 2022 peak and the 2026 decline
| Year | US adult obesity rate | Notes |
|---|---|---|
| 2019 | 33.6% | Pre-pandemic baseline |
| 2021 | 38.2% | Post-pandemic surge |
| 2022 | 39.9% | All-time recorded high |
| 2023 (NHANES) | ~40.3% | Clinical measurement |
| 2025 | ~37% | First sustained Gallup decline |
| 2026 (Gallup) | 36.4% | Lowest since 2018 |
The 2022 peak is significant for context. Multiple factors drove it: disrupted healthcare access during COVID, reduced physical activity, increased stress eating, and the closure of gyms, parks, and outdoor spaces. The 3.5 percentage point drop to 36.4% by mid-2026 represents an estimated 7.6 million fewer obese adults compared with three years earlier, per Gallup’s own analysis.
This is the first time in the modern obesity epidemic that a consistent multi-year downward trend has been observed at the population level.
Severe obesity: the more alarming trend
Severe obesity — defined as a BMI of 40 or higher — has roughly doubled in the past 24 years, from 4.7% in 1999–2000 to 9.7% in 2021–2023. This growth has outpaced the rise in general obesity.
Severe obesity carries disproportionately higher health risks than obesity in general. It’s more strongly associated with type 2 diabetes, heart failure, joint disease requiring surgery, and significantly reduced life expectancy. It also costs more to treat — people with severe obesity have medical costs 2–3 times higher than people with healthy weight.
The 2026 GLP-1 data is particularly relevant here: clinical trials show these medications produce the most dramatic weight loss results in people with the highest starting BMI. Zepbound, for example, helped patients with BMI ≥35 lose an average of 22.5% of body weight in SURMOUNT-1. For someone at BMI 45, that’s a reduction that can move them out of the severe obesity category entirely.
Obesity by age group
Obesity prevalence varies significantly across age groups and shows distinct trajectories.
| Age group | Obesity prevalence (NHANES 2021–2023) |
|---|---|
| Adults 20–39 | 35.5% |
| Adults 40–59 | 46.4% (highest) |
| Adults 60 and older | 38.9% |
| Children 2–19 | 21.1% (record high) |
Middle-aged adults (40–59) have the highest obesity rates of any age group. This has been consistent for over a decade and reflects the accumulated effect of decades of metabolic changes, slowing metabolism, and lifestyle factors.
Children and adolescents present the most concerning trend. The childhood obesity rate has more than tripled since the mid-1970s, reaching 21.1% in the 2021–2023 NHANES cycle — a record high. Children with obesity are significantly more likely to become obese adults, creating a compounding effect on future healthcare burden.
Obesity by race and ethnicity
Obesity rates show wide and persistent racial and ethnic disparities that reflect structural inequities in food access, healthcare, and economic opportunity.
| Racial/ethnic group | Adult obesity prevalence |
|---|---|
| Non-Hispanic Black adults | 49.9% |
| Hispanic adults | 45.6% |
| Non-Hispanic White adults | 41.4% |
| Non-Hispanic Asian adults | 16.1% |
Non-Hispanic Black adults have the highest obesity rates — nearly three times higher than Asian adults. These gaps have not narrowed over time. They’re driven by well-documented structural factors: unequal access to affordable healthy food, food deserts in predominantly Black and Latino neighborhoods, fewer safe spaces for physical activity, under-resourced healthcare, and the documented metabolic effects of chronic stress from systemic racism and economic inequity.
For children living below the poverty level, the obesity rate is 24.1% — more than double the 10.4% rate among children from families at four times the poverty level.
Obesity by geography
Obesity is not evenly distributed across the US. The Southeast and Appalachian regions consistently have the highest rates; the West Coast and Mountain West tend to be lower.
- Highest obesity states (2024 BRFSS): Mississippi, West Virginia, Louisiana, Arkansas, Alabama — all above 38%
- Lowest obesity states: Colorado (~23%), Hawaii (~24%), Massachusetts (~27%)
- 19 states had adult obesity rates at or above 35% in 2024 — down from 23 states in 2023
No US state is below 20% adult obesity. Colorado, long the “thinnest” state, now sits where Mississippi was in the 1990s.
The health consequences of obesity
Obesity is not a cosmetic condition. It’s a chronic disease that dramatically raises the risk of serious and expensive health conditions.
- Metabolic: Type 2 diabetes (~23% of adults with obesity are diabetic), insulin resistance, fatty liver disease (NAFLD).
- Cardiovascular: Hypertension affects 58% of adults with obesity. Obesity is the primary driver of heart disease, the leading cause of death in the US.
- Cancer: Obesity is associated with increased risk for 13 types of cancer, including breast, colon, endometrial, esophageal, and kidney cancers. This makes it the second-leading preventable cause of cancer after smoking.
- Respiratory: Obstructive sleep apnea affects 40%+ of adults with obesity. Even a 10% reduction in body weight improves sleep apnea severity significantly — which is one reason GLP-1 drugs gained FDA approval for OSA.
- Musculoskeletal: Arthritis affects 30% of adults with obesity. Every pound of excess weight adds roughly four pounds of force on the knee joint.
- Mental health: Obesity is associated with significantly elevated rates of depression, anxiety, and social isolation — and these relationships run in both directions.
The economic cost of obesity in the US
The financial burden of obesity on the US healthcare system is enormous and growing.
- $445 billion per year in total direct and indirect costs (WorldMetrics, 2026)
- $173 billion per year in direct medical costs in 2019 dollars (inflated substantially by 2026)
- 20–21% of all US annual medical spending is obesity-related
- $20.4 trillion in projected direct healthcare costs from obesity between 2023 and 2060 (PubMed, 2025 model)
- 40% of all US diabetes healthcare spending is caused by obesity
- Childhood obesity costs the system $12.7–14.3 billion annually in direct medical costs alone
These numbers don’t fully capture the indirect economic costs: lost workplace productivity, disability claims, reduced income potential, and the ripple effect of a less healthy workforce on economic output. When those are included, the annual cost approaches and may exceed $445 billion.
An obese adult costs the healthcare system on average $1,500–2,000 more per year than an adult with healthy weight. A child with obesity costs approximately $237 more per year in total medical costs than a healthy-weight peer — seemingly modest, but multiplied across 15 million obese children, it adds up fast.
What is driving the 2026 decline in adult obesity?
The decline from 39.9% in 2022 to 36.4% in 2026 is unprecedented in the history of US obesity tracking. Researchers have pointed to one primary driver: GLP-1 receptor agonist adoption.
As of June 2026, 11% of US adults currently take a GLP-1 drug for weight loss — roughly 28 million people. The inverse correlation between GLP-1 adoption and the falling obesity rate is statistically clear and temporally consistent: the obesity rate began falling within two years of Wegovy’s FDA approval in June 2021 and has tracked downward as prescription rates climbed.
This is the first time in the modern obesity epidemic that a pharmacological intervention has produced a measurable population-level change in obesity prevalence. Previous public health campaigns — food labeling, physical activity guidelines, sugar taxes, school nutrition programs — produced no sustained national-level decline.
The decline is not equally distributed. Adults under 65 who have access to GLP-1s through commercial insurance or self-pay programs are driving most of the reduction. Older adults, who until July 2026 lacked Medicare coverage for weight-loss GLP-1s, haven’t seen the same benefit yet.
For a full picture of GLP-1 adoption trends, see our GLP-1 usage statistics guide.
Childhood obesity: the exception to the improving trend
The adult trend is improving. The childhood trend is not.
The 2021–2023 NHANES data, released in 2026 by the CDC, found that 21.1% of US children and teenagers ages 2–19 have obesity — a record high, up from 19.3% in 2017–2018. Additionally:
- 7% of children and adolescents have severe obesity
- 15.1% are overweight
GLP-1 drugs are FDA-approved for adolescents 12 and older in some cases, but access and prescription rates remain very low in this age group. The driving factors for childhood obesity — ultra-processed food consumption, screen time, reduced physical activity, and poverty — have not improved and in some cases have worsened.
Children with obesity face a significantly elevated risk of becoming obese adults, setting up the next generation’s health burden before it starts.
Where obesity rates are heading
The trajectory for adults looks cautiously optimistic for the first time in decades. Three forces are reinforcing the decline:
- Expanded GLP-1 access. The Medicare GLP-1 Bridge program launched July 1, 2026, extending coverage to millions of older Americans. As coverage expands and prices fall (self-pay options now start at $149–$299/month), more qualifying patients will reach treatment.
- Better drugs. The pipeline includes retatrutide, which produced 28.3% average weight loss in Phase 3 trials, with an NDA expected in Q4 2026. Greater efficacy per patient translates to more population-level impact.
- Longer-term treatment. As more patients stay on GLP-1 drugs for 2+ years, the cumulative population effect on body weight will grow. Most of the current GLP-1 cohort is still in the early phases of treatment.
The countervailing risk is also real. Federal cuts to CDC chronic disease prevention programs, rollbacks to nutrition assistance, and reduced community health funding could blunt the gains before they consolidate. The Healthy People 2030 national goal is a 36.0% obesity rate — a number the 2026 Gallup data suggests is now within reach for the first time.
Conclusion
The 2026 obesity picture in the US is a story of slow progress complicated by persistent inequality and an unresolved childhood crisis. Adult obesity is declining for the first time in modern tracking history — from 39.9% in 2022 to 36.4% today — driven by GLP-1 drug adoption. The economic burden remains enormous at ~$445 billion annually, the health consequences affect every major organ system, and racial and socioeconomic disparities are as wide as ever.
The most important development is that the trend has reversed. That has never happened before. Whether it continues and deepens depends on how broadly effective treatments become accessible — to older adults through Medicare, to lower-income patients through Medicaid, and to the 57 million privately insured adults who qualify but still lack coverage.
The tools to meaningfully reduce obesity in America now exist. The question is whether the healthcare system can get them to the people who need them.
If you qualify for weight loss treatment and want to understand your options, book a free consultation with Heally — licensed providers available same day in 40+ states.
FAQ
What is the current obesity rate in the US?
Approximately 36.4% of US adults have obesity, according to Gallup’s June 2026 health survey — the lowest rate since 2018. The most recent clinical measurement from CDC NHANES (2021–2023) put the rate at 40.3%. The true current rate likely sits between these figures, around 37–39%.
Is obesity increasing or decreasing in the US?
Adult obesity is declining for the first time in the modern obesity epidemic. The rate peaked at 39.9% in 2022 and has fallen to 36.4% by mid-2026, a decline researchers attribute directly to GLP-1 drug adoption. Childhood obesity is not declining — it reached a record high of 21.1% in the most recent CDC data.
How many Americans are obese?
Approximately 90–100 million US adults have obesity, depending on which data source and year you use. At 40.3% of 260 million adults (NHANES), that’s about 105 million. At the Gallup 36.4% estimate, it’s around 95 million.
Which racial group has the highest obesity rate in the US?
Non-Hispanic Black adults have the highest adult obesity prevalence at 49.9%, compared with 45.6% for Hispanic adults, 41.4% for White adults, and 16.1% for Asian adults, according to the most recent NHANES data.
What is the economic cost of obesity in the US?
Total direct and indirect costs of obesity reach approximately $445 billion annually. Direct medical costs alone are estimated at $173 billion per year in 2019 dollars — significantly higher in inflation-adjusted 2026 terms. A 2025 PubMed projection puts the total direct cost at $20.4 trillion between 2023 and 2060 if trends continue.
What are the most common health conditions caused by obesity?
The most common obesity-related conditions are hypertension (58% of adults with obesity), type 2 diabetes (~23%), obstructive sleep apnea (40%+), arthritis (30%), and cardiovascular disease. Obesity also raises the risk of 13 types of cancer.
What percentage of US children have obesity?
21.1% of US children and teens ages 2–19 have obesity, according to the 2021–2023 NHANES data — a record high. An additional 15.1% are overweight.
Why is obesity higher in the Southeast US?
The highest-obesity states — Mississippi, West Virginia, Louisiana, Arkansas, Alabama — share several factors: higher rates of poverty, limited access to fresh food, fewer safe spaces for outdoor activity, lower rates of health insurance coverage, and higher rates of chronic disease generally. These are largely structural rather than behavioral differences.
Related reading on Heally:
- How many Americans are using weight loss drugs in 2026?
- How weight loss actually works: calories, metabolism, and hormones
- Why you stop losing weight: metabolic adaptation explained
- Taking Ozempic to lose belly fat: what to expect in 2026
- Semaglutide dosing guidelines: a complete schedule for 2026
Sources
- Gallup — In US, GLP-1 usage reaches new high; obesity rate falls to 36.4% (July 2026)
- CDC NCHS — Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023 (Data Brief No. 508)
- CDC NCHS — Childhood obesity: 21.1% of children ages 2–19 (NHANES 2021–2023)
- GoalBMI / WorldMetrics — Obesity statistics America 2026: $445B economic burden
- The Global Files — American obesity rate by year statistics 2026; state-by-state BRFSS data
- PubMed — US healthcare system will spend $20.4 trillion on obesity 2023–2060
- FAIR Health — GLP-1 use for obesity increased 587% from 2019 to 2024
- Forbes Health — Obesity in America: statistics and facts (2026)
Data disclaimer: Statistics reflect surveys and surveillance data available as of July 2026. Gallup data is self-reported; NHANES clinical measurement data lags by approximately 2–3 years. Both are cited where applicable.